Apart from its hematopoietic function, erythropoietin (Epo) exerts neuroprotective functions in brain hypoxia and ischemia. To examine the mechanisms mediating Epo's neuroprotective activity in vivo, we made use of our transgenic mouse line tg21 that constitutively expresses human Epo in brain without inducing excessive erythrocytosis. We show that human Epo is expressed in tg21 brains and that cortical and striatal neurons carry the Epo receptor. After middle cerebral artery occlusion, human Epo potently protected brains of tg21 mice against ischemic injury, both when severe (90 min) and mild (30 min) ischemia was imposed. Histochemical studies revealed that Epo induced an activation of JAK-2, ERK-1/-2, and Akt pathways in the ischemic brain. This activation was associated with elevated Bcl-X L and decreased NO synthase-1 and -2 levels in neurons. Intracerebroventricular injections of selective inhibitors of ERK-1/-2 (PD98059) or Akt (wortmannin) pathways revealed that both ERK-1/-2 and Akt were required for Epo's neuroprotective function, antagonization of either pathway completely abolishing tissue protection. On the other hand, ERK-1/-2 and Akt blockade did not reverse the neuronal NO synthase-1/-2 inhibition, indicating that Epo down-regulates these NO synthases in an ERK-1/-2 and Akt independent manner. On the basis of our data, the dual activation of ERK-1/-2 and Akt is crucial for Epo's neuroprotective activity.
Very recently, a novel heterodimeric Epo receptor has been described that might be responsible for Epo's neuroprotective functions (12) . Downstream of this receptor, the signaling mechanisms responsible for Epo's neuroprotective functions in vivo are still largely unknown. Understanding these mechanisms, however, is crucial for future developments of neuroprotective compounds. To elucidate its neuroprotective properties, we recently investigated the effects of Epo on the delayed degeneration of retinal ganglion cells, which are central nervous system (CNS)-derived neurons, in a transgenic mouse line, termed tg21 (8) . The tg21 mouse constitutively expresses human Epo in the brain without inducing erythrocytosis (13, 14) and is therefore attractive for neuroprotection studies. In our present study, we submitted tg21 mice to intraluminal middle cerebral artery (MCA) occlusions and analyzed the effects of endogenously overexpressed Epo on brain injury and cell signaling. By selectively blocking individual signaling pathways with specific signal transduction inhibitors in vivo, we characterized the signaling pathways mediating Epo's brain protective function.
MATERIALS AND METHODS

Animal surgery
Experiments were performed in accordance to the Swiss guidelines for the care and use of laboratory animals and approved by local government authorities (Kantonales Veterinäramt Zürich). Male tg21 mice, aged 8-10 weeks, expressing human Epo under control of the human PDGF B-chain promoter (HindIII-XmnI fragment; see Ref. 13 ) or wild-type control animals were anesthetized with 1% halothane (30% O 2 , remainder N 2 O). Rectal temperature was maintained between 36.5 and 37.0°C using a feedback-controlled heating system. Focal ischemia was induced using an intraluminal technique, as described previously (15, 16) , using a 8-0 silicon-coated (Xantopren: Bayer Dental, Osaka, Japan) nylon monofilament (Ethilon; Ethicon, Norderstedt, Germany). During the experiments, laser Doppler flow (LDF) was monitored with a flexible fiber optic probe (Perimed, Stockholm, Sweden) attached to the intact skull overlying the MCA territory. LDF changes were measured during ischemia and up to 30 min after reperfusion onset. At that time, anesthesia was discontinued. After 24 h (90 min MCA occlusion; n=5 animals/group; see Ref. 15) or 72 h (30 min ischemia; n=6 animals/group; see Ref. 17 ) of reperfusion, neurological deficits were evaluated using a five-point neurological deficit score ranging from 0 = normal function to 4 = absence of spontaneous motor activity. Animals were then deeply anesthetized and decapitated. Brains were quickly removed and frozen on dry ice. Coronal 18-μm sections were prepared on a cryostat.
Analysis of histological injury
Cresyl violet staining
Brain sections from five equidistant rostrocaudal brain levels, 2 mm apart, were stained. Sections were digitized, and the border between infarcted and noninfarcted tissue was outlined using an image analysis system (Image J; National Institute of Health, Bethesda, MD). The area of infarction, the infarct volume, and brain swelling on these sections were analyzed.
Terminal transferase biotinylated-dUTP nick end labeling (TUNEL)
Adjacent sections were fixed with 4% paraformaldehyde/0.1 M phosphate-buffered saline (PBS). After labeling with terminal desoxynucleotidyl transferase (TDT) mix, containing 12.5 mg/ml TDT (Boehringer-Mannheim, Mannheim, Germany) and 25 mg/ml biotinylated dUTP (Boehringer-Mannheim), sections were incubated with streptavidin-fluorescein isothiocyanate (FITC), counterstained with 4',6-diaminido-2-phenylidole (DAPI) and coverslipped. Sections were evaluated by one of the examiners blinded for the experimental condition (Ü. Kilic) by counting DNA-fragmented cells in a total of six regions of interest of the striatum, each measuring 62,500 µm 2 , as described previously (18) . Mean values were calculated for all regions.
Brain angiograms
In additional animals (n=3/mouse line), brain angiograms were prepared in anesthetized mice by injecting black latex (38°C) through a PE10 catheter into the animals' aorta (0.3 ml/animal over 20 s) (16, 19) . Ten minutes later, animals were decapitated and brains were removed. Photographs were taken of the dorsal brain surfaces, which allowed localization of the anastomotic lines between the MCA and anterior cerebral artery territories, as previously reported (16) . The distance from midline to the line of anastomosis was measured at the levels of the striatum and thalamus (i.e., 4 and 6 mm from frontal brain pole). This procedure allowed us to evaluate the size of the MCA territory.
Radio immunoassay of tissue Epo levels
Further animals (n=3/mouse line) were used for determination of Epo brain levels using an 125 IEpo-based radioimmunoassay (RIA) (Amersham, Zurich, Switzerland), according to previously published protocols (20) . Shortly, tissue samples from the animals' striatum and overlying cortex were obtained from the MCA territory, which were homogenized in a lysis buffer (containing 150 mM NaCl; 10 mM EDTA; 50 mM Tris-HCl; 0.25% Triton; 0.1% NP-40 and protein inhibitors) and centrifuged at 15,000 rpm for 25 min. Total protein concentrations were calculated using a bicinchoninic acid (BCA) protein assay (pierce) reagent. The lower detection limit of our RIA was 4 U/l, the intrassay/interassay variances <2% and <6%. All Epo measurements were performed in duplicate. Mean values were calculated for both measurements.
Immunohistochemistry for Epo receptor, NO synthase (NOS)-1/-2, and activated caspase-3
Brain sections were fixed in 4% paraformaldehyde/0.1 M PBS, washed, and immersed for 1 h in 0.1 M PBS containing 0.3% triton (PBS-T)/10% normal goat serum (NGS). Sections were incubated overnight at 4°C with polyclonal rabbit anti-Epo receptor (H-194, sc-5624; Santa Cruz, Nunningen, Switzerland), anti-NOS-1 (nNOS, sc-1025; Santa Cruz), anti-NOS-2 (iNOS, sc-650; Santa Cruz) or antiactivated caspase-3 (CM-1; BD Biosciences, Basel, Switzerland) antibodies, diluted 1:100 in PBS-T, and subsequently stained with a Cy-3 labeled secondary antibody. Counterstainings were performed with a mouse antibody directed against the neuronal marker NeuN (MAB377, Chemikon, Lucerne, Switzerland; 1:500) that was detected with FITC. Sections were finally incubated with DAPI and coverslipped. Brain sections were evaluated under a fluorescence microscope using appropriate filters. Expression levels were also analyzed Western blots for cell signaling factors and Bcl-X L Tissue samples harvested from the ipsilateral (ischemic) and contralateral (nonischemic) striatum of wild-type and tg21 mice subjected to 30 min of MCA occlusion were complemented with lysis buffer, homogenized, and centrifuged. Supernatants were used for sodium dodecylsulfate-PAGE (SDS-PAGE). Before processing, samples from animals belonging to the same experimental group were pooled (n=6/group). After SDS-PAGE, proteins were transferred onto PVDF membranes. Membranes were dried overnight, incubated in blocking solution and immersed with rabbit anti-phospho-JAK-2 (3771; Cell Signaling, Allschwil, Switzerland), rabbit anti-total (= detecting both the phosphorylated and unphosphorylated forms) Akt (9272; Cell Signaling), rabbit anti-phospho-Akt (9271; Cell Signaling), rabbit anti-total extracellularregulated kinase (ERK)-1/-2 (9102; Cell Signaling), mouse anti-phospho-ERK-1/-2 (M8159; Sigma, Deisenhofen, Germany), rabbit anti-total Jun kinase (JNK)-1/-2 (JNK-2, sc-572; Santa Cruz), rabbit anti-phospho-JNK-1/-2 (9251; Cell Signaling) or rabbit anti-Bcl-X (610212; BD Biosciences) antibody, each diluted 1:500 in 0.1% Tween 20/ 0.1 M Tris-buffered saline (TBS). Membranes were rinsed, incubated in peroxidase-coupled secondary antibodies, diluted 1:2000 in 0.1% Tween 20/0.1 M TBS, washed, immersed in enhanced chemoluminescence (ECL) solution and exposed to ECL-Hyperfilm (Amersham, Braunschweig, Germany). Protein loading was controlled using a monoclonal mouse antibody against anti-β-actin (A5316; Sigma). Blots were performed at least 3 times in order to confirm data reproducibility. Protein levels were analyzed densitometrically, corrected with values determined on anti-β-actin blots and expressed as relative values compared with wild-type mice.
Inhibition of ERK-1/-2 and phosphatidyl inositol-3 kinase (PI3K)/Akt pathways
By means of a glass microelectrode with a tip outer diameter of 50 µm, 2 µl of 1) 100% DMSO (DMSO), 2) the mitogen activated protein (MAP) kinase/ERK kinase-1 (MEK-1) inhibitor PD98059 (0.2 mM; New England Biolabs GmbH, Schwalbach, Germany), dissolved in 100% DMSO or 3) the PI3K/Akt inhibitor wortmannin (0.1 mM; Sigma, St. Louis, MO), dissolved in 100% DMSO, was carefully injected into the intracerebroventricular space (n=6 tg21 animals/ group). Thirty minutes later, animals were submitted to MCA occlusions for 30 min, according to the same procedure as described above. Seventy-two hours later, animals were deeply reanesthetized and killed. Brains were removed, frozen on dry ice, and cut on a cryostat into 18-μm sections. TUNEL and immunohistochemical stainings for NOS-1 and -2 were then prepared.
Data analysis and statistics
Data were analyzed by two-tailed t tests (comparisons between 2 groups), one-way ANOVA, followed by LSD tests (comparisons between ≥3 groups) using SPSS for Windows 10.1. Results are presented as means ± SD values; n values indicate the number of different samples analyzed. P values less than 0.05 were considered significant.
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RESULTS
Human Epo is expressed in the cerebral cortex and striatum of tg21 mice
To determine whether our tg21 mouse indeed expressed human Epo in the brain, we performed RIA measurements with tissue samples obtained from the cerebral cortex and underlying striatum, which are the main structures forming the MCA territory. Compared with wild-type animals, Epo levels were elevated ~2.1-fold in tg21 mice (Fig. 1 ).
Brain neurons express the Epo receptor
To determine whether brain neurons of wild-type and tg21 mice similarly express the Epo receptor, immunohistochemical stainings were prepared. Microscopic analysis revealed a robust expression of Epo receptor on NeuN+ neurons both in the cerebral cortex and striatum ( Fig. 2A,  B) . Expression levels of Epo receptor did not differ between wild-type and tg21 mice ( Fig. 2A,  B) .
The Epo receptor-associated protein JAK-2 is activated by human Epo
To find out whether human Epo activates JAK-2, which binds with Epo receptor in vitro and mediates Epo receptor signaling into the cytosol (reviewed by Sirén et al. (4)), we performed Western blots for the phosphorylated, that is, activated JAK-2 protein. Increased phosphorylation levels of JAK-2 in the brains of tg21 mice (Fig. 3) indicated that JAK-2 activation took place in the presence of human Epo, thereby confirming that the Epo receptor is functional in tg21 mice.
Cerebral blood flow is not influenced by human Epo
To ensure the reproducibility of ischemias and to rule out hemodynamic differences between wild-type and tg21 mice, LDF was recorded above the MCA territory during ischemia and up to 30 min after reperfusion. LDF analysis did not exhibit any differences between wild-type and tg21 mice, either following 90 min (Fig. 4A ) or 30 min (Fig. 5 ) of MCA occlusion. Insertion of the monofilament reproducibly resulted in a decline of blood flow to ~15-20% of preischemic levels (Fig. 4A, 5 ). Monofilament retraction was rapidly followed by a restoration of blood flow to basal values in animals submitted to 90 min MCA occlusion (Fig. 4A) . In animals undergoing 30 min of ischemia, a short-lasting hyperperfusion response was found shortly after reperfusion onset (to ~120-140% of preischemic) (Fig. 5 ).
Neuronal expression of Epo reduces ischemic infarct volume and brain swelling, and improves neurological deficits
Brain infarcts were morphologically evaluated by cresyl violet staining at 24 h after 90 min MCA occlusion. In wild-type animals, reproducible brain infarcts were noted under these conditions (Fig. 4B, E) . Infarcts always involved both cortical and striatal areas and were consistently associated with brain swelling (Fig. 4C ) and neurological deficits (Fig. 4D) . Human Epo reduced infarct volume by ~84% (Fig. 4B) , drastically diminished brain edema (Fig. 4C) , and improved the behavioral changes (Fig. 4D) . Note that tg21 animals exhibited small striatal infarcts that almost completely spared the cerebral cortex (Fig. 4E) . To exclude that differences in infarct size in tg21 mice were influenced by macroscopic differences of the brain vasculature,
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a phenomenon that exists when different mouse strains are compared (19) , latex angiograms were prepared. These angiograms allow us to outline the size of the MCA territory by tracing the anastomotic line between the MCA and anterior cerebral artery territories (see also Ref. 16 ). In our studies, the anatomical localization of the anastomotic line did not differ between wild-type and tg21 mice, indicating that MCA territories were identical in size (Fig. 4F) . Our data confirm that the reduction of infarct size seen was indeed evoked by Epo.
Epo prevents disseminated neuronal injury and reduces neuronal NOS-1 and -2 expression
Whereas brain infarcts in animals undergoing 90 min MCA occlusion involved both the striatum and overlying cortex, 30 min of ischemia resulted in disseminated neuronal injury only in the striatum, but not the cortex, as analyzed by TUNEL staining (Fig. 6A, B) and activated caspase-3 immunohistochemistry (Fig. 6A, C) 3 days after reperfusion. Transgenic Epo significantly decreased the density of injured cells in the striatum (Fig. 6A-C) . Neurological deficits after 30 min MCA occlusion were always mild (deficit score ≤1, irrespective of the mouse genotype) and were therefore not further evaluated.
To characterize mechanisms mediating Epo's neuroprotective function, immunohistochemical stainings for NOS-1 and NOS-2 were analyzed. Microscopic analysis revealed that tissue protection by Epo was associated with decreased NOS-1 (Fig. 6A, D) and NOS-2 (Fig. 6A, E ) levels in animals subjected to 30 min of ischemia. Double stainings for the neuronal marker NeuN revealed that NO synthase immunoreactivity was localized in neurons (Fig. 6A, E) .
Epo activates ERK-1/-2, Akt, JNK and Bcl-X L signaling
To further analyze cell signaling pathways responsible for Epo's neuroprotective properties, we performed Western blots with tissue samples obtained from the mouse striatum. Blots of nonischemic tissue showed that total levels of ERK-1/-2, Akt, and JNK-1/-2 (assessed with antibodies recognizing both the phosphorylated and unphosphorylated proteins) did not differ between tg21 and wild-type animals (Fig. 7) . Importantly, however, phosphorylated, i.e., activated ERK-1/-2, Akt, and JNK-1/-2 levels were higher, while Bcl-X L expression was slightly lower in tg21 than wild-type mice (Fig. 7) .
Upon ischemia, phosphorylated but not total levels of ERK-1/-2 and JNK-1/-2 further increased in tg21 animals but remained unchanged or decreased in wild-type mice (Fig. 7) . Akt phosphorylation remained high in tg21 animals (Fig. 7) . Bcl-X L expression increased above levels of wild-type mice (Fig. 7) . Our data suggested a role of ERK-1/-2, Akt, and Bcl-X L pathways in Epo's neuroprotective function.
Epo's neuroprotective function in vivo requires dual activation of ERK-1/-2 and Akt
To define as whether ERK-1/-2 or Akt signaling pathways were responsible for Epo's neuroprotective function, we applied the signal transduction inhibitors PD98059 (ERK-1/-2) or wortmannin (Akt) into the intracerebroventricular space. Interestingly, both inhibitors completely abolished the tissue neuroprotection induced by Epo (Fig. 6A-C) . Our data indicate that Epo's neuroprotective activity crucially depends on the dual activation of both pathways.
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Inhibition of NO synthases by human Epo does not depend on ERK-1/-2 and Akt
To determine whether ERK-1/-2 or Akt mediates the inhibition of NOS-1 and -2 by human Epo, we also prepared immunohistochemical stainings of animals treated with PD98059 and wortmannin. In the brains examined, neither ERK-1/-2 (PD98059) nor Akt (wortmannin) inhibition restored NOS-1 and -2 levels in ischemic neurons (Fig. 6A, D, E) . This observation indicates that the NOS-1 and -2 inhibition by Epo occurs in an ERK-1/-2-and Akt-independent manner.
DISCUSSION
Using the transgenic mouse line tg21 that expresses human Epo in the CNS, we demonstrate that the hematopoietic growth factor Epo protects against focal cerebral ischemia in vivo via ERK-1/-2 and Akt signaling. Already by the mid 1990s, it was realized that Epo, apart from its expression in the liver and kidney, is expressed in the CNS of rodents, monkeys, and humans (21, 22) . After observations that induction of Epo in the brain takes place in an oxygendependent manner via activation of hypoxia-inducible factor-1 (HIF-1) (2, 23), it was subsequently shown that HIF-1-induced Epo expression is involved not only in high altitude adaptation, but also mediates resistance against ischemic stroke (3, 4) . Indeed, recent clinical studies have proven that Epo protects stroke patients against ischemic damage (9) . These data evoked great excitement in the field, since they provided evidence that neuroprotection is feasible in human patients. Until now, there had been no clinically applicable compound with proven neuroprotection efficacy.
Tg21 mice as model for neuroprotection studies
Despite being in clinical trials, little was known about the signaling mechanisms mediating Epo's neuroprotective activity in vivo. This may be due to the fact that conventional systemic delivery of Epo invariably causes fluctuations of tissue Epo levels, which in turn lead to variable signaling responses. The tg21 mouse appeared particularly suitable for deciphering Epo's protective functions, since it shows a very stable expression of human Epo in the brain, without inducing excessive erythrocytosis. In fact, blood hematocrit in these animals is normal (~42%). Effects of transgenic Epo have previously been assessed in another mouse line, tg6, in which Epo levels are elevated not only in the brain but also in blood plasma (14) . As a consequence, blood hematocrit in these animals is markedly increased (up to 80%). When submitted to focal ischemia, tg6 mice revealed enlarged brain infarcts, an effect that can be attributed to hemodynamic disturbances brought about by the elevated blood viscosity.
Epo's neuroprotective activity in vivo involves ERK-1/-2 and PI3K/ Akt signaling
In contrast to mice with excessive erythrocytosis, we show in the present study that human Epo markedly protected tg21 mice from ischemic injury. Thus, neuroprotection was observed both after long-lasting ischemias (90 min MCA occlusion), where infarct volume was reduced by ~84%, as well as after mild ischemias (30 min) leading to disseminated neuronal injury. Our data confirm that Epo is a highly potent neuroprotectant. Our pharmacological studies revealed that Epo's neuroprotective action was mediated via the dual activation of both ERK-1/-2 and PI3K/ Akt pathways. Antagonization of either signaling pathway with the ERK-1/-2 inhibitor PD98059 and PI3K/ Akt inhibitor wortmannin completely reversed Epo's neuroprotection in vivo, which indicates that both pathways are required for sustained tissue protection. In brain ischemia, the delivery of signal transduction inhibitors is a well-established approach. When delivered via intracerebroventricular application, PD98059 (24) and wortmannin (25) induce a potent inhibition of ERK-1/-2 and Akt pathways in the brain. In nontransgenic animals, PD98059 and wortmannin do not aggravate ischemic injury, as previously shown (24, 25) . PD98059 given at identical concentration even mediated neuroprotection after 30 min MCA occlusion (24) , while wortmannin had no influence on neuronal viability after brain ischemia, even at much higher doses (25) . The absence of an injury-aggravating effect in nontransgenic animals shows that the infarct changes induced by PD98059 and wortmannin in tg21 mice indeed reflected specific actions on cell signaling, rather than unspecific side effects of the two compounds.
Role of mitochondrial signaling pathways in Epo's neuroprotective function
Although in vitro studies already suggested that Epo modulates ERK-1/-2 (4) and PI3K/ Akt (26), our earlier findings following retinal ganglion cell axotomy, a model of subacute CNS neuronal degeneration, indicated that Epo's protective function in these neurons is predominantly driven by ERK-1/-2 (8). On the basis of our present data, Epo's neuroprotective action in brain ischemia differs from models of more delayed neurodegeneration in the sense that not only ERK-1/-2 but also Akt is required for neuronal survival. In ischemic neurons, Akt signaling exhibits a strong stabilizing influence on mitochondrial function that plays a crucial role in ischemic injury. Via phosphorylation of Bad, activated Akt releases Bcl-X L inside the mitochondria (27) , which, in turn, prevents formation of the mitochondrial permeability transition pore. Bcl-X L , on the other hand, once released from Bad, inhibits the secretion of cytochrome c from injured mitochondria, thereby impeding activation of executioner caspases-9 and -3 (15). Our observation of elevated Bcl-X L levels in ischemic tg21 mice, which we again had not seen after retinal ganglion cell axotomy (8) , underlines the importance of mitochondrial signaling after stroke and confirms earlier in vitro findings suggesting a role of Bcl-X L in Epo's neuroprotective activity (26, 28) .
Transgenic Epo activates JNK-1/-2 signaling
In line with in vitro studies demonstrating that Epo activates JNK-1/-2 signaling (29, 30) , transgenic Epo also stimulated JNK-1/-2 phosphorylation after focal cerebral ischemia. Similar to ERK-1/-2, JNK-1/-2 also belongs to the MAP kinase family, mediating stress responses to ischemia (31) . Pharmacological inhibition of JNK-1/-2 prevented mitochondrial Bax translocation (32) and reduced brain injury after stroke (33) . On the basis of its potential deathpromoting activity, an involvement of JNK-1/-2 in Epo's neuroprotective function seemed unlikely. We therefore did not modulate JNK-1/-2 activity pharmacologically. We interpret the JNK-1/-2 response as a stress reaction of the rescued tissue. It is noteworthy that we did not see this JNK-1/-2 activation after optic nerve transection (34) . Our data suggest that the role of JNK-1/-2 depends on the type of tissue and experimental model used, which is in line with observations in the literature that JNK-1/-2 activation differs strongly between model systems (31) .
Inhibition of NO synthases by Epo does not depend on ERK-1/-2 and Akt signaling
Apart from the activation of ERK-1/-2, Akt, and JNK-1/-2, an inhibition of NOS-1 and -2 by human Epo was noted in our studies. Immunocytochemical double stainings confirmed that NOS expression was localized in neurons. Interestingly, the NOS-1/-2 inhibition was not reversed either by the ERK-1/-2 inhibitor PD98059 or the PI3K/ Akt inhibitor wortmannin, suggesting that NOS-1/-2 inhibition by Epo occurs in an ERK-1/-2-and Akt-independent manner. Inhibition of NOS-1 and -2 by Epo has not yet been shown after brain ischemia. Inhibition of NOS-2 has previously been described following splanchnic artery occlusion, in which it was interpreted as part of a mechanism protecting against endotoxin-induced shock (35) . The inhibition of NOS-1 and -2 by human Epo may be a hitherto unknown player also in the context of Epo's neuroprotective function. Indeed, both NO synthase isoforms are known to exacerbate ischemic damage after stroke, as they contribute to free radical stress in the brain parenchyma, via formation of nitrite and nitrate (36) . On the basis of our data, Epo may protect the brain tissue by reducing tissue levels of these highly toxic compounds.
OUTLOOK
After the proof-of-concept trial by Ehrenreich and coworkers (9) , which proved the safety and efficacy of recombinant Epo in ischemic stroke patients, chances appear favorable that it will soon be possible to establish a clinically applicable neuroprotection therapy in humans based on Epo. Very recently, hopes were fostered by studies from the pharmaceutical industry developing carbamylated derivatives of Epo that exhibit neuroprotective but not erythropoietic actions (37) . The successful development of a treatment would not only create new perspectives for neurological therapy and raise hopes for millions of patients concerned, but also have favorable consequences for health care systems, as clinical improvements would invariably result in reduced rehabilitation costs. The more than 80% reduction of infarct volume seen in ischemic tg21 animals after focal cerebral ischemia confirms that human Epo is indeed a very potent neuroprotectant. Notably, Epo's actions in our present study were superior to other growth factors that we previously examined in our laboratory, such as glial cell line-derived neurotrophic factor (GDNF) (18) , ciliary neurotrophic factor (CNTF) (18) , vascular endothelial growth factor (VEGF) (16) , and melatonin (34) . We believe that the high potency of Epo is attributed to its dual action on ERK-1/-2 and Akt pathways, which may provide a more powerful neuronal rescue, than when only a single signaling pathway is activated. The development of clinical neuroprotection therapies will deserve concerted efforts in the near future, as a priority issue in clinical neurosciences. measurements (A), infarct volumes (B), brain swelling (C), and neurological deficits (D) are shown for wild-type (wt) and tg21 mice. Cresyl violet sections at the level of the striatum are presented for all animals (E), and results from vascular angiograms are also depicted (F). Note the remarkable reduction in infarct size by almost 85% induced by human Epo (B, E), which is associated with reduced brain edema (C) and improved neurological deficits (D). Furthermore, note that the reduction of infarct size is neither attributed to differences in cerebral blood flow (A) nor to differences in the vascular anatomy of the MCA territory, reflected by the localization of the anastomotic line between the MCA and anterior cerebral artery territory, which was analyzed at the level of the mouse striatum and thalamus (F). Data are means ± SD values (n=5 animals/group (A-E) n=3 animals/group (F)). *P < 0.05 compared with wild-type mice. Scale Bar: 1 mm. Western blots with brain tissue homogenates of wild-type (wt) and tg21 mice obtained from the ischemic striatum are presented. Note that phosphorylated, but not total levels of ERK-1/-2, Akt, and JNK-1/-2, as well as Bcl-X L expression, are increased by human Epo. Our data indicate that ERK-1/-2, Akt, and Bcl-XL are involved in Epo's neuroprotective function. Data are means ± SD values (n=3 different samples/ group), normalized with corresponding blots for β-actin, which are also shown. I, ischemic; C, contralateral nonischemic. *P < 0.05 compared with wild-type mice; #P < 0.05 compared with nonischemic tissue.
